SELECT PUBLICATIONS

Gradishar W et al. Cost-effectiveness of nanoparticle albumin-bound paclitaxel versus docetaxel in the treatment of metastatic breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 5044.

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Ibrahim NK et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23(25):6019-26. Abstract

Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 40.

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevaci­zumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005a;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract

Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): A newer taxane alternative in breast cancer. Future Oncol 2005;1(6):755-62. Abstract

Nyman DW et al. A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies. Proc ASCO 2004;Abstract 2027.

Nyman DW et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23(31):7785-93. Abstract

O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long term disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.

Perez EA et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005;6(5):425-32. Abstract

Robert N et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2073.

Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.

Sparano JA et al. Phase III study of doxorubicin-cyclophosphamide followed by pacli­taxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium 2005;Abstract 48.

Stinchcombe TE et al. Preliminary results of phase I trial of carboplatin (CP) in combi­nation with ABI-007 administered weekly or every 3 weeks in patients (pts) with solid tumors. San Antonio Breast Cancer Symposium 2005;Abstract 1092.

Young O et al. Randomized pre-operative study of 750 mg of fulvestrant and 20 mg tamoxifen in premenopausal women with estrogen receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 5084.